Agios' Rare Anemia Drug Application Under FDA Priority Review - Agios Pharmaceuticals (NASDAQ:AGIO)

The FDA has accepted Agios Pharmaceuticals Inc's (NASDAQ:AGIO) marketing application seeking approval for mitapivat for pyruvate kinase (PK) deficiency.
Under Priority Review designation, the agency's action date is assigned as of February 17, 2022.
Related: Agios Pharma Files US Application For Mitapivat In PK Deficiency.
Mitapivat application is under review with the European Medical Agency for the same indication.
Pyruvate kinase (PK) deficiency is a rare, inherited disease that presents chronic hemolytic anemia, the accelerated destruction of red blood cells.
Related content: Benzinga's Full FDA Calendar.
Price Action: AGIO shares closed 2.38% higher at $44.65 on Tuesday.

To add Benzinga News as your preferred source on Google, click here.